---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-040848"
form_type: "8-K"
ticker: "LQDA"
cik: "0001819576"
company_name: "Liquidia Corp"
filed_at: "2023-04-03T23:59:59+00:00"
generated_at: "2026-06-17T07:12:41.154024+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Liquidia and GSK restructure PRINT license; Liquidia gains rights for most inhaled uses

## Summary
- New non-exclusive, royalty-free license replaces 2012 collaboration; GSK gets pre-clinical research rights only.
- Liquidia may apply PRINT to all inhaled formulations except certain GSK proprietary molecules.
- GSK must seek expanded license for clinical/commercial use; Liquidia retains ownership of its technology.
- Agreement effective March 31, 2023; press released April 3, 2023.

## SEC filing metadata
- accession: 0001104659-23-040848
- form_type: 8-K
- ticker: LQDA
- cik: 0001819576
- company_name: Liquidia Corp
- filed_at: 2023-04-03T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 1.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1819576/000110465923040848/0001104659-23-040848-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1819576/000110465923040848/tm2311372d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-040848
- JSON: https://secwatch.observer/filing/0001104659-23-040848.json
- Plain text: https://secwatch.observer/filing/0001104659-23-040848.txt

## Key facts
- Material Agreements
  Liquidia Corp entered into Research License Agreement with Glaxo Group Limited (GSK) (effective 2023-03-31).
  - Action: entry
  - Agreement: license
  - Counterparty: Glaxo Group Limited (GSK)
  - Effective: 2023-03-31
  source text: On March 31, 2023, Liquidia Corporation, a Delaware corporation (the “Company”) through Liquidia Technologies, Inc., a Delaware corporation (“Liquidia Technologies”) and wholly owned subsidiary of the Company, entered into a Research License Agreement (the “Agreement”) with Glaxo Group Limited, a company organized and existing under the laws of England (“GSK”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1819576/000110465923040848/0001104659-23-040848-index.htm
- Material Agreements
  Liquidia Corp terminated Inhalation Collaboration and Option Agreement with Glaxo Group Limited (GSK) (effective 2023-03-31).
  - Action: termination
  - Agreement: collaboration
  - Counterparty: Glaxo Group Limited (GSK)
  - Effective: 2023-03-31
  source text: The Agreement supersedes and replaces that certain Inhalation Collaboration and Option Agreement, dated as of June 15, 2012, by and between Liquidia Technologies and GSK, as amended on May 13, 2015, November 19, 2015 and June 24, 2019 (the “Prior Agreement”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1819576/000110465923040848/0001104659-23-040848-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.